Weinnovate Biosolutions Gets Featured In List of Top 10 Biotech Companies 2021

September 27: Weinnovate Biosolutions Private Limited (WIBPL) gets featured in the top 10 biotech companies in 2021 list with pioneer Indian biotechnology institutes like the Serum Institute and Biocon. The Pune, Maharashtra-based company, WIBPL, has been listed in the prestigious top 10 biotech companies in 2021 list for developing antimicrobial solutions that reduce incidences of Hospital Acquired Infections (HAI).

The ISO-certified Startup company, WIBPL, has been founded by Dr. Milind Choudhari CEO, Dr. Anupama S. Engineer, and Dr. Prasad Bhagat in 2016. The sole purpose of the company is to serve quality and affordable infection prevention & control healthcare solutions. “We develop quality and affordable biotechnology solutions without compromise”, says Dr. Milind Choudhari, Founder and CEO of WIBPL. They are a dedicated team of technologists and scientists that aim to provide efficient, rapid, affordable, and advanced healthcare solutions.

Hospital Acquired Infections (HAI) are those infections that people usually catch while they are hospitalized. Hospital Acquired Infections (HAI) is one of the leading causes of morbidity and mortality across the globe. To prevent the spread of HAIs, the need for effective infection prevention policies and control procedures is quintessential. The spread of HAIs is a huge cost for both the hospital as well as the patient. While they increase a patient’s length of stay in the hospital as well as finances. In the case of the hospitals, they lead to longer bed occupancy and reduces the number of patients they could serve instead. Some common types of HAIs are bloodstream infections, surgical site infections, urinary tract infections, ventilator-associated – pneumonia, and other nosocomial infections.

The hospital management, physician, nursing staff, central sterilization service, food service, laundry service, housekeeping, and infection control team play a huge role in preventing the spread of HAIs. Every individual and healthcare service provider is equally responsible for the prevention of HAIs. However, the absence of trained health workers, incompetent surveillance, limited staff training, less focus on prevention activities, non-operational national and regional prevention programs are some of the biggest loopholes in existing prevention solutions.

HAIs are spreading like wildfire despite the implementation of existing prevention solutions. Realizing the need of the hour several biotechnology companies have come up with new and innovative biotechnology solutions. One such incredible solution is the WIBPL’s unique, patented, and next-generation antimicrobial device, ‘SilvoGuard’ Antimicrobial Medical device. The SilvoGuard medical devices prevent the spread of HAIs by preventing bacterial adhesion and biofilm formation on the surfaces of medical devices. The main objective is to ensure zero infections occur during the stay of a patient in the hospital.

SilvoGuard Antimicrobial Medical devices are based upon the next-gen NanoAgCide technology. The technology is a colloidal and antimicrobial silver nanoparticle solution that has been clinically tested for being highly effective. From making the product services non-toxic to antimicrobial for lifetime use, WIBPL’s products like SilvoGuard Antimicrobial Foley Catheter prevent the spread of infections and reduce intake of antibiotics to control it. Thus, money saved by using SilvoGuard overweighs the amount spent otherwise on antibiotic treatments, diagnostic tests, etc. in case infection occurs.

Medical devices are responsible for a large portion of nosocomial infections, particularly in critically ill patients. Device-associated infections can cause major medical and economic sequelae. Amongst HAI, 80% of cases of urinary tract infection are catheter-related. Catheter is one of the fast running medical consumables used for all bed-ridden patients for assisting urination. Catheter-Associated Urinary Tract Infections (CA-UTI) results in prolonged hospital stay by almost 17 days and adds to increased hospital bill. The average rate of occupancy of bed for any hospital is also detrimentally affected by CAUTI. With such background, it is of utmost importance to use an antimicrobial catheter that will prevent the incidences of UTI. WIBPL has designed SilvoGuard Antimicrobial Foley catheter, which is made 100% antimicrobial using its patented silver nanoparticle technology. SilvoGuard Antimicrobial Foley Catheters have clinically proven to inhibit the occurrence of UTI. SilvoGuard catheters are environmentally friendly and does not contain any toxic chemicals. Currently, CAUTI is addressed by administering empirical, broad-spectrum antibiotics to the patients who are catheterized. Such empirical antibiotic treatment can lead to the rise of antimicrobial resistance and multi-drug resistant pathogens.

In only a few months duration, the SilvoGuard Antimicrobial catheters have been used across hospitals all over India. More than 10,000 patients have been catheterized with SilvoGuard Catheters and have been successfully saved from the risk of developing CA-UTI. WIBPL aims to touch more than 50,000 lives in 2021-22. The catheters have been thoroughly tested by several third parties, and studies have been published highlighting the efficiency of the SilvoGuard catheters. Several more peer-reviewed publications are on the way for SilvoGuard. Sharing the vision with WIBPL to make India AtmaNirbhar by using Make-In-India healthcare products, the company has been backed by one of India’s top Venture Capitalists, Chiratae Ventures. With this financial muscle backing, the company aims to grow massively in years to come.

Check out the top10 list at:

https://www.theindustryoutlook.com/manufacturing/ranking/top-10-biotechnology-companies-2021-rid-164.html

Learn More about them at http://www.weinnovatebiosolutions.com/

https://www.silvoguard.com